Blocking RUNX1 to Stop Eye Scarring and Cell Changes

This patent describes using methods and substances to stop certain cells in the eye from growing too much or changing their type, which can cause serious eye conditions like scarring.

What it covers

The patent describes ways to prevent or reduce the unwanted growth or movement of cells in the retina, which is the light-sensing part of the eye. It also aims to stop a process called 'epithelial to mesenchymal transition' (EMT) in eye cells, and potentially cells from other body parts. This involves using specific compositions and formulations to target these cellular activities. For instance, in conditions like proliferative vitreoretinopathy, where scar tissue forms in the eye, this invention could provide a treatment to slow down or stop the cells that cause this scarring from multiplying and spreading.

What it doesn't cover

• —Does not cover treatments for eye conditions that do not involve the RUNX1 protein.
• —Does not cover methods that increase, rather than reduce, cell growth or movement.
• —Does not cover diagnostic tools for identifying proliferative vitreoretinopathy.
• —Does not cover treatments for conditions where epithelial to mesenchymal transition is beneficial.
• —Does not cover therapies that do not involve specific compositions or formulations.

The clever bit

The clever bit is identifying RUNX1 as a specific protein target whose inhibition can prevent or reduce unwanted cell growth and transformation in the eye. This offers a precise molecular approach to tackle complex conditions like proliferative vitreoretinopathy and other diseases driven by epithelial to mesenchymal transition.

Why it matters

Proliferative vitreoretinopathy (PVR) is a severe complication of retinal detachment surgery, often leading to blindness due to scar tissue formation. Current treatments are often surgical and have limited success. This patent matters because it proposes a new molecular target, RUNX1, for drug development, offering a potential non-surgical or adjunctive therapy to prevent or slow down this devastating condition. It also addresses epithelial to mesenchymal transition, a fundamental process in many diseases beyond the eye, suggesting broader implications for drug discovery.

Real-world examples

• 1.Future drug candidates for proliferative vitreoretinopathy
• 2.Therapeutic eye drops or injections targeting RUNX1
• 3.Drugs for fibrotic diseases involving EMT